On November 18, 2024 VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), reported it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo) granting Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China) (Press release, Avenzo Therapeutics, NOV 18, 2024, View Source [SID1234648481]). VelaVigo will maintain rights for Greater China and plans to collaborate with Avenzo in global development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The partnership with Avenzo is a validation of VelaVigo’s strong antibody and ADC discovery engine for First-in-Class/Best-in-Class (FIC/BIC) molecules. I’m proud of our team’s achievement in bringing multiple molecules to IND-enabling stage within 3 years and look forward to continued advancement of our pipeline", said Jing Li, founder, Chairman and CEO of VelaVigo. "Partnership is an integral part of VelaVigo’s strategy to bring our novel pipeline to patients in need and maximize value for our investors. We look forward to advancing the development of our Nectin4/TROP2 ADC program globally with Avenzo’s strong expertise", commented Tong Zhang, co-founder, CBO and CFO of VelaVigo.
Since its inception in 2021, VelaVigo has built an extensive pipeline of over ten FIC/BIC multi-specific antibodies and ADC molecules for oncology and autoimmune diseases. It has also set up VelaVigo Bio, Inc. in the US to drive clinical development and partnership globally.
Under the terms of the agreement, VelaVigo will receive an upfront fee and potential near-term milestones upon option exercise by Avenzo of up to $50 million. In addition, VelaVigo is eligible to receive future potential development, regulatory, and commercial milestone payments of up to approximately $750 million in total, as well as tiered royalties on sales in Avenzo’s territory.
An Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (FDA) and Chinese National Medical Products Administration (NMPA) in 2025.